News | Vena Cava Filters | December 04, 2018

First BTG Sentry Bioconvertible IVC Filter Implanted in U.S.

Filter bioconverts after period of transient risk of pulmonary embolism, leaving patent, unobstructed IVC lumen

First BTG Sentry Bioconvertible IVC Filter Implanted in U.S.

December 4, 2018 — BTG plc announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device, a bioconvertible inferior vena cava (IVC) filter. The BTG Sentry filter is designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen. This eliminates the need to retrieve and addresses the typical filter-related complications associated with conventional IVC filters.

Ayad K.M. Agha, M.D., director of interventional radiology and an interventional radiologist at Cardiovascular Interventional Radiology Centers in Phoenix, who performed the procedure on one of his patients, said: “Traditional IVC filters are sometimes associated with a variety of concerns. Placing the BTG Sentry filter gives me confidence in reducing potential complications seen with conventional filters. Using the BTG Sentry IVC filter only requires one visit which means my patient doesn’t have to worry about coming back to make sure the filter is retrieved. This is better for the patient and their families and removes the risk of any complications that may arise on a follow-up procedure”

The BTG Sentry filter is supported by two years of data available through the SENTRY Trial. The data was recently presented on podium at VIVA in Las Vegas, and demonstrated no instances of filter tilt, migration, embolization, fracture or IVC perforation through 24-months of imaging-intensive follow-up.

U.S. Food and Drug Administration 510(k) clearance for the Sentry device was obtained in 2017.

For more information: www.btgplc.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now